ArticleThe British journal of ophthalmology2020
Moorfields AMD database report 2: fellow eye involvement with neovascular age-related macular degeneration.
Article in The British journal of ophthalmology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 31 citations in OpenAlex.
- Preliminary Observations of Bilateral Neovascular Age-Related Macular Degeneration Progression: A Real-World Retrospective Case Series.Journal of clinical medicine · 2026Article
- Beyond Cost: Faricimab as a Driver of Service Efficiency and Quality in Neovascular Age-Related Macular Degeneration Care.Ophthalmology and therapy · 2026Article
- Rapid Macular Thinning as a Biomarker for Geographical Atrophy.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
- Incidence and risk factors of fellow-eyes wet conversion in unilateral neovascular age-related macular degeneration over 15-year follow-up.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2025Article
- Prevention Surpasses Treatment: 5-year Follow-Up, Cost-Utility, and Cost-Benefit of Zeaxanthin Therapy for Neovascular Age-Related Macular Degeneration.Ophthalmology and therapy · 2023Article
- Early Optical Coherence Tomography Biomarkers for Selected Retinal Diseases-A Review.Diagnostics (Basel, Switzerland) · 2023Review
- Second eyes to develop neovascular age-related macular degeneration have fewer symptoms and better one-year visual outcomes.BMC ophthalmology · 2023Article
- Practical implementation of a q4-q16 aflibercept treat-and-extend pathway for the treatment of neovascular age-related macular degeneration: Updated guidance from a UK expert panel.Eye (London, England) · 2023Article
- Associations with baseline visual acuity in 12,414 eyes starting treatment for neovascular AMD.Eye (London, England) · 2023Article
- Impact of COVID-19 Confinement on Quality of Life of Patients with Age-Related Macular Degeneration: A Two-Wave Panel Study.Journal of clinical medicine · 2023Article
- Characterising treatment outcomes of patients achieving quarterly aflibercept dosing for neovascular age-related macular degeneration: real-world clinical outcomes from a large tertiary care centre.Eye (London, England) · 2023Article
- Consequences of Real-World Surveillance of Fellow Eyes in Neovascular Age-Related Macular Degeneration.Life (Basel, Switzerland) · 2023Article
- What about the fellow eye in treatment of neovascular age-related macular degeneration? Analysis of data from the Swedish macula register.Acta ophthalmologica · 2022Observational
- Choriocapillaris Flow Imbalance in Fellow Eyes in Age-Related Macular Degeneration.Investigative ophthalmology & visual science · 2022Article
- AlzEye: longitudinal record-level linkage of ophthalmic imaging and hospital admissions of 353 157 patients in London, UK.BMJ open · 2022Article
- [Real-life results of anti-VEGF treatment in fellow eyes with nAMD].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2022Article
- A Systematic Review of Carotenoids in the Management of Age-Related Macular Degeneration.Antioxidants (Basel, Switzerland) · 2021Review
- Quantitative Analysis of OCT for Neovascular Age-Related Macular Degeneration Using Deep Learning.Ophthalmology · 2021Article
- Predicting wet age-related macular degeneration (AMD) using DARC (detecting apoptosing retinal cells) AI (artificial intelligence) technology.Expert review of molecular diagnostics · 2021Article
- Influence of unilateral intravitreal bevacizumab injection on the incidence of symptomatic choroidal neovascularization in the fellow eye in patients with neovascular age-related macular degeneration (Review).Experimental and therapeutic medicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 4 countries.
Funding
Abstract
BACKGROUND/
aimsNeovascular age-related macular degeneration (nAMD) is frequently bilateral, and previous reports on 'fellow eyes' have assumed sequential treatment after a period of treatment of the first eye only. The aim of our study was to analyse baseline characteristics and visual acuity (VA) outcomes of fellow eye involvement with nAMD, specifically differentiating between sequential and non-sequential (due to macular scarring in the first eye) antivascular endothelial growth factor treatment and timelines for fellow eye involvement.
methodsRetrospective, electronic medical record database study of the Moorfields AMD database of 6265 patients/120 286 single entries with data extracted between 21 October 2008 and 9 August 2018. The data set for analysis consisted of 1180 sequential, 807 non-sequential and 3410 unilateral eyes.
resultsMean VA (ETDRS letters±SD) of sequentially treated fellow eyes at baseline was significantly higher (63±13), VA gain over 2 years lower (0.37±14) and proportion of eyes with good VA (≥70 letters) higher (46%) than the respective first eyes (baseline VA 54±16, VA gain at 2 years 5.6±15, percentage of eyes with good VA 39%). Non-sequential fellow eyes showed baseline characteristics and VA outcomes similar to first eyes. Fellow eye involvement rate was 32% at 2 years, and median time interval to fellow eye involvement was 71 (IQR: 27-147) weeks.
conclusionThis report shows that sequentially treated nAMD fellow eyes have better baseline and final VA than non-sequentially treated eyes after 2 years of treatment. Sequentially treated eyes also had a greater proportion with good VA after 2 years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.